Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

EPR26-163: The Epidemiology of Second Primary Lung Cancer: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Program.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

QIM26-303: An Innovative Team Approach to Standardize SCLC Care Delivery Across an Integrated Health System.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Cut, Clip, Burn: A Combined Approach to Lung Cancer and Atrial Fibrillation.

Annals of thoracic surgery short reports·2026
Same author

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Cancer·2026
Same journal

Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer.

Clinical lung cancer·2026
Same journal

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Clinical lung cancer·2026
Same journal

Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report.

Clinical lung cancer·2026
Same journal

Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer.

Clinical lung cancer·2026
Same journal

Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis.

Clinical lung cancer·2026
Same journal

Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan.

Clinical lung cancer·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Combined SCLC clinical and pathologic characteristics.

Shahab Babakoohi1, Pingfu Fu, Michael Yang

  • 1Division of Hematology and Oncology, Case Western Reserve University, University Hospital Case Medical Center, Cleveland, OH, USA.

Clinical Lung Cancer
|September 27, 2012
PubMed
Summary
This summary is machine-generated.

Patients with combined small-cell lung cancer (C-SCLC) have a better prognosis and are more likely to receive surgery than those with pure small-cell lung cancer (SCLC). This study highlights improved survival outcomes for C-SCLC patients.

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Related Experiment Videos

Last Updated: May 18, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Area of Science:

  • Oncology
  • Pulmonary Medicine
  • Cancer Research

Background:

  • Limited data exists on combined small-cell lung cancer (C-SCLC), which features both small-cell and non-small-cell components.
  • Pure small-cell lung cancer (SCLC) has a well-characterized clinical course.

Purpose of the Study:

  • To compare the clinicopathological characteristics and survival outcomes of patients with C-SCLC versus pure SCLC.
  • To identify prognostic factors in C-SCLC patients.

Main Methods:

  • Retrospective analysis of 1628 lung cancer cases over a decade.
  • Identification and review of 22 C-SCLC patients.
  • Comparison of C-SCLC patient data with 406 pure SCLC patients.

Main Results:

  • Combined small-cell and large-cell carcinoma was the most frequent C-SCLC subtype.
  • C-SCLC patients demonstrated significantly higher overall survival (median 15 months) compared to pure SCLC (median 10.8 months).
  • Surgery was performed more frequently in C-SCLC patients (45%) than in pure SCLC patients (3%).

Conclusions:

  • Combined small-cell lung cancer patients exhibit a better prognosis than those with pure SCLC.
  • C-SCLC patients are more likely to be candidates for surgical intervention.
  • Survival benefit in C-SCLC appears linked to surgical treatment, as no difference was observed in non-surgically treated groups.